<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="topic" /><meta name="keywords" content="Continuous infusion devices; Infusion devices, continuous; Syringe drivers, palliative care; Palliative care: subcutaneous infusion; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Convulsions: palliative care; Midazolam: palliative care; Haloperidol: palliative care; Levomepromazine: palliative care; Cyclizine: palliative care; Metoclopramide: nausea and vomiting: palliative care; Octreotide: palliative care; Pain: palliative care; Diamorphine: pain: palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care; Midazolam: palliative care; Syringe drivers, palliative care: mixing and compatibility; Syringe drivers, palliative care: problems; Morphine: analgesia: diamorphine equivalence; Diamorphine: morphine equivalence: subcutaneous infusion" /><meta name="IX" content="Continuous infusion devices; Infusion devices, continuous; Syringe drivers, palliative care; Palliative care: subcutaneous infusion; Colic, bowel, palliative care; Hyoscine hydrobromide: palliative care: excessive respiratory secretions; Hyoscine hydrobromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: bowel colic; Hyoscine butylbromide: palliative care: excessive respiratory secretions; Glycopyrronium bromide: palliative care; Convulsions: palliative care; Midazolam: palliative care; Haloperidol: palliative care; Levomepromazine: palliative care; Cyclizine: palliative care; Metoclopramide: nausea and vomiting: palliative care; Octreotide: palliative care; Pain: palliative care; Diamorphine: pain: palliative care; Restlessness, palliative care; Confusion, palliative care; Haloperidol: palliative care; Levomepromazine: palliative care; Midazolam: palliative care; Syringe drivers, palliative care: mixing and compatibility; Syringe drivers, palliative care: problems; Morphine: analgesia: diamorphine equivalence; Diamorphine: morphine equivalence: subcutaneous infusion" /><title>Continuous infusion devices: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="29476.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="29476.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=29476.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="29403.htm">Guidance on prescribing</a> &gt; <a href="29446.htm">Prescribing in palliative care</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="29458.htm" title="Previous: Miscellaneous conditions">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="29485.htm" title="Next: Prescribing for the elderly">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_29476">Continuous infusion devices</h1><?highlighter on?><div id="pC" class="jN"><p>Although drugs can usually
be administered <i>by mouth</i> to control the symptoms
of advanced cancer, the parenteral route may sometimes be necessary.
Repeated administration of <i>intramuscular injections</i> can be difficult in a cachectic patient. This has led to the use
of portable continuous infusion devices, such as syringe drivers, to
give a <i>continuous subcutaneous infusion</i>,
which can provide good control of symptoms with little discomfort
or inconvenience to the patient.</p><div class="cN"><h3 class="cBP">Syringe driver rate settings</h3><p>Staff using syringe drivers should be <b>adequately trained</b> and different rate settings should be <b>clearly identified</b> and <b>differentiated</b>; incorrect use of syringe drivers
is a common cause of medication errors.</p></div><p>Indications for the <b>parenteral route</b> are:</p><ul class="cBF"><li><p class="cQ">the patient is unable to take medicines by mouth owing
to <i>nausea and vomiting, dysphagia, severe weakness,</i> or <i>coma;</i> </p></li><li><p class="cQ">there is <i>malignant bowel obstruction</i> in
patients for whom further surgery is inappropriate (avoiding the need
for an intravenous infusion or for insertion of a nasogastric tube); </p></li><li><p class="cQ">occasionally when the patient <i>does not wish</i> to take regular medication by mouth.</p></li></ul><div id="_120046"><div class="cAZ"><h2>Bowel colic and excessive respiratory secretions</h2> <p class="cAX"><span>Hyoscine hydrobromide</span> effectively reduces respiratory secretions and bowel colic and is
sedative (but occasionally causes paradoxical agitation); it is given
in a <i>subcutaneous infusion dose</i> of 1.2–2 mg/24 hours.</p><p><span>Hyoscine butylbromide</span> is
used for bowel colic and for excessive respiratory secretions, and
is less sedative than <span>hyoscine hydrobromide</span>. Hyoscine
butylbromide is given in a <i>subcutaneous infusion dose</i> of 60–300 mg/24 hours for bowel colic and 20–120 mg/24 hours for
excessive respiratory secretions (<b>important:</b> these
doses of <i><span>hyoscine butylbromide</span></i> must not be confused with the much lower dose of <span><i>hyoscine hydrobromide</i></span>, above).</p><p>Glycopyrronium 0.6–1.2 mg/24 hours by subcutaneous infusion may also
be used to treat bowel colic or excessive respiratory secretions.</p></div></div><div id="_201719"><div class="cAZ"><h2>Convulsions</h2> <p class="cAX">If a patient has previously been receiving an antiepileptic
drug <i>or</i> has a primary or secondary cerebral tumour <i>or</i> is at risk of convulsion (e.g. owing to uraemia) antiepileptic
medication should not be stopped. <span>Midazolam</span> is the benzodiazepine
antiepileptic of choice for <i>continuous subcutaneous infusion</i>, and it is given initially in a dose of 20–40 mg/24 hours.</p></div></div><div id="_120003"><div class="cAZ"><h2>Nausea and vomiting</h2> <p class="cAX"><span>Haloperidol</span> is given
in a <i>subcutaneous infusion dose </i>of 2.5–10 mg/24 hours.</p><p><span>Levomepromazine</span> is given in a <i>subcutaneous
infusion dose</i> of 5–25 mg/24 hours but sedation can limit
the dose. </p><p><span>Cyclizine</span> is particularly likely to precipitate if mixed
with diamorphine or other drugs (see under Mixing and Compatibility,
below); it is given in a <i>subcutaneous infusion dose</i> of 150 mg/24 hours.</p><p>Metoclopramide can cause skin reactions; it is given
in a <i>subcutaneous infusion dose</i> of 30–100 mg/24 hours.</p><p><span>Octreotide</span> (<a title="sub-sub-section: Somatostatin analogues" href="4840.htm#_4840">section 8.3.4.3</a>), which stimulates water and
electrolyte absorption and inhibits water secretion in the small bowel,
can be used by subcutaneous infusion in a dose of 250–500 micrograms/24 hours
to reduce intestinal secretions and to reduce vomiting due to bowel
obstruction. Doses of 750 micrograms/24 hours, and occasionally higher,
are sometimes required.</p></div></div><div id="_120543"><div class="cAZ"><h2>Pain control</h2> <p class="cAX">Diamorphine is the preferred opioid since its high
solubility permits a large dose to be given in a small volume (see
under Mixing and Compatibility, below). The table <a title="target-block: Equivalent doses of morphine sulphate" href="29476.htm#_120035">below</a> shows approximate equivalent
doses of morphine and diamorphine.</p></div></div><div id="_5.13"><div class="cAZ"><h2>Restlessness and confusion</h2> <p class="cAX"><span>Haloperidol</span> has little sedative effect; it is given in a <i>subcutaneous
infusion dose</i> of 5–15 mg/24 hours.</p><p><span>Levomepromazine</span> has a sedative effect; it is given in an
initial <i>subcutaneous infusion dose</i> of 12.5–50 mg/24
hours, titrated according to response (doses greater than 100 mg/24
hours should be given under specialist supervision).</p><p><span>Midazolam</span> is a sedative and an antiepileptic that
may be used in addition to an antipsychotic drug in a very restless
patient; it is given in an initial <i>subcutaneous infusion dose</i> of 10–20 mg/24 hours, titrated according to response (usual dose
20–60 mg/24 hours).</p></div></div><div class="cAZ"><h2>Mixing and compatibility</h2> <p class="cAX">The general
principle that injections should be given into separate sites (and
should not be mixed) does not apply to the use of syringe drivers
in palliative care. Provided that there is evidence of compatibility,
selected injections can be mixed in syringe drivers. Not all types
of medication can be used in a subcutaneous infusion. In particular,
chlorpromazine, prochlorperazine, and diazepam are <b>contra-indicated</b> as they cause skin reactions at the injection site; to a lesser
extent cyclizine and levomepromazine also sometimes cause local irritation.</p><p>In theory injections dissolved in water for injections are more
likely to be associated with pain (possibly owing to their hypotonicity).
The use of physiological saline (sodium chloride 0.9%) however increases
the likelihood of precipitation when more than one drug is used; moreover
subcutaneous infusion rates are so slow (0.1–0.3 mL/hour) that pain
is not usually a problem when water is used as a diluent.</p><p>Diamorphine can be given by subcutaneous infusion in a strength
of up to 250 mg/mL; up to a strength of 40 mg/mL either <i>water
for injections</i> or <i>physiological saline</i> (sodium
chloride 0.9%) is a suitable diluent—above that strength only <i>water for injections</i> is used (to avoid precipitation).</p><p>The following can be mixed with <i>diamorphine</i>:</p><table class="table" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;"><colgroup><col /><col /></colgroup><tbody><tr><td style="">Cyclizine<sup class="footnote"><a title="Go to footnote" href="29476.htm#footnote119647">(1)</a></sup></td><td style="">Hyoscine hydrobromide</td></tr><tr><td style="">Dexamethasone<sup class="footnote"><a title="Go to footnote" href="29476.htm#footnote119648">(2)</a></sup></td><td style="">Levomepromazine</td></tr><tr><td style="">Haloperidol<sup class="footnote"><a title="Go to footnote" href="29476.htm#footnote119649">(3)</a></sup></td><td style="">Metoclopramide<sup class="footnote"><a title="Go to footnote" href="29476.htm#footnote119650">(4)</a></sup></td></tr><tr><td style="">Hyoscine butylbromide</td><td style="">Midazolam</td></tr></tbody></table><p>Subcutaneous infusion solution should be monitored
regularly both to check for precipitation (and discoloration) and
to ensure that the infusion is running at the correct rate.</p></div><div class="cAZ"><h2>Problems encountered with syringe drivers</h2> <p class="cAX">The following
are problems that may be encountered with syringe drivers and the
action that should be taken:</p><ul class="cBF"><li><p class="cQ">if the subcutaneous infusion runs <i>too quickly</i> check the rate setting and the calculation; </p></li><li><p class="cQ">if the subcutaneous infusion runs <i>too slowly</i> check the start button, the battery, the syringe driver, the cannula,
and make sure that the injection site is not inflamed;</p></li><li><p class="cQ">if there is an <i>injection site reaction</i> make sure that the site does not need to be changed—firmness or
swelling at the site of injection is not in itself an indication for
change, but pain or obvious inflammation is.</p></li></ul></div><div id="_120035"><div class="cBM" id="_tb0004">Equivalent doses of morphine sulphate and diamorphine hydrochloride
given over 24 hours</div><table class="table" summary="Equivalent doses of morphine sulphate and diamorphine hydrochloride&#xA;given over 24 hours" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /><col /></colgroup><thead><tr><th style="border-bottom: 1pt solid ; " colspan="3"><b>These equivalences are <i>approximate only</i> and should be adjusted according to response </b></th></tr><tr><th style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;" colspan="2">MORPHINE </th><th style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;">PARENTERAL DIAMORPHINE </th></tr><tr style=""><th style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;">Oral <br />morphine<br /> sulphate<br /></th><th style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;">Subcutaneous<br /> infusion of <br />morphine sulphate </th><th style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;">Subcutaneous<br /> infusion of <br />diamorphine hydrochloride</th></tr></thead><tbody><tr style=""><td style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;"><b>over 24 hours</b></td><td style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;"><b>over 24 hours</b></td><td style="border-bottom: 1pt solid ; text-align: center;vertical-align: middle;"><b>over 24 hours</b></td></tr><tr><td style="text-align: center;">30 mg</td><td style="text-align: center;">15 mg</td><td style="text-align: center;">10 mg</td></tr><tr><td style="text-align: center;">60 mg</td><td style="text-align: center;">30 mg</td><td style="text-align: center;">20 mg</td></tr><tr><td style="text-align: center;">90 mg</td><td style="text-align: center;">45 mg</td><td style="text-align: center;">30 mg</td></tr><tr><td style="text-align: center;">120 mg</td><td style="text-align: center;">60 mg</td><td style="text-align: center;">40 mg</td></tr><tr><td style="text-align: center;">180 mg</td><td style="text-align: center;">90 mg</td><td style="text-align: center;">60 mg</td></tr><tr><td style="text-align: center;">240 mg</td><td style="text-align: center;">120 mg</td><td style="text-align: center;">80 mg</td></tr><tr><td style="text-align: center;">360 mg</td><td style="text-align: center;">180 mg</td><td style="text-align: center;">120 mg</td></tr><tr><td style="text-align: center;">480 mg</td><td style="text-align: center;">240 mg</td><td style="text-align: center;">160 mg</td></tr><tr><td style="text-align: center;">600 mg</td><td style="text-align: center;">300 mg</td><td style="text-align: center;">200 mg</td></tr><tr><td style="text-align: center;">780 mg</td><td style="text-align: center;">390 mg</td><td style="text-align: center;">260 mg</td></tr><tr><td style="text-align: center;">960 mg</td><td style="text-align: center;">480 mg</td><td style="text-align: center;">320 mg</td></tr><tr><td style="text-align: center;">1200 mg</td><td style="text-align: center;">600 mg</td><td style="text-align: center;">400 mg</td></tr><tr><td style="border-bottom: 1pt solid ; " colspan="3">If breakthrough pain occurs give a subcutaneous (preferable) or intramuscular injection equivalent to one-tenth to one-sixth of the total 24-hour subcutaneous infusion dose. It is kinder to give an intermittent bolus injection <i>subcutaneously</i>—absorption is smoother so that the risk of adverse effects at peak absorption is avoided (an even better method is to use a subcutaneous butterfly needle).<br />To minimise the risk of infection no individual subcutaneous infusion solution should be used for longer than 24 hours.</td></tr></tbody></table></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="29458.htm">Previous: Miscellaneous conditions</a> | <a class="top" href="29476.htm#">Top</a> | <a accesskey="]" href="29485.htm">Next: Prescribing for the elderly</a> ►</div><div class="cF"><div class="footnote" id="footnote119647"><sup>(1)</sup>Cyclizine may precipitate at concentrations above 10 mg/mL <i>or</i> in the presence of sodium chloride 0.9% <i>or</i> as the concentration of diamorphine relative to cyclizine increases;
mixtures of diamorphine and cyclizine are also likely to precipitate
after 24 hours.</div><div class="footnote" id="footnote119648"><sup>(2)</sup>Special care is needed to avoid precipitation of dexamethasone
when preparing it.</div><div class="footnote" id="footnote119649"><sup>(3)</sup>Mixtures of haloperidol and diamorphine are likely to precipitate
after 24 hours if haloperidol concentration is above 2 mg/mL.</div><div class="footnote" id="footnote119650"><sup>(4)</sup>Under some conditions infusions containing metoclopramide become
discoloured; such solutions should be discarded.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>